Oxaliplatin salvage for recurrent ovarian cancer: a single institution's experience in patient populations with platinum resistant disease or a history of platinum hypersensitivity.

[1]  A. Jemal,et al.  Cancer statistics, 2013 , 2013, CA: a cancer journal for clinicians.

[2]  M. Shahin,et al.  A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a Gynecologic Oncology Group study. , 2011, Gynecologic oncology.

[3]  B. Dörken,et al.  Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. , 2011, European journal of cancer.

[4]  M. Saif,et al.  Hypersensitivity Reactions Associated with Platinum Antineoplastic Agents: A Systematic Review , 2010, Metal-based drugs.

[5]  A. Kotanidou,et al.  Acute hypersensitivity reactions to chemotherapy agents: an overview. , 2010, Inflammation & allergy drug targets.

[6]  A. Grothey,et al.  Phase 2 Trial of Docetaxel, Gemcitabine, and Oxaliplatin Combination Chemotherapy in Platinum- and Paclitaxel-Pretreated Epithelial Ovarian Cancer , 2009, International Journal of Gynecologic Cancer.

[7]  T. Hickish,et al.  Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Robert S Mannel,et al.  Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  M. Piccart,et al.  Oxaliplatin/5fluorouracil-based chemotherapy was active and well tolerated in heavily pretreated patients with ovarian carcinoma , 2008, Archives of Gynecology and Obstetrics.

[10]  A. Norman,et al.  Capecitabine and oxaliplatin for advanced esophagogastric cancer. , 2008, The New England journal of medicine.

[11]  Michael W Sill,et al.  Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  A. Oza,et al.  Optimal chemotherapy treatment for women with recurrent ovarian cancer , 2007, Current oncology.

[13]  N. Petrelli,et al.  Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  C. Thomssen,et al.  Phase II trial of docetaxel and carboplatin in recurrent platinum-sensitive ovarian, peritoneal and tubal cancer. , 2007, Gynecologic oncology.

[15]  S. Waggoner,et al.  Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study. , 2006, Gynecologic oncology.

[16]  T. Conroy,et al.  Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer--a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Robert S Mannel,et al.  Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  M. Morgan,et al.  Phase II study of oxaliplatin in platinum-resistant and refractory ovarian cancer: a gynecologic group study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  V. Torri,et al.  Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial , 2003, The Lancet.

[20]  P. Rose,et al.  A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study. , 2003, Gynecologic oncology.

[21]  J. Essigmann,et al.  Mechanisms of resistance to cisplatin. , 2001, Mutation research.

[22]  P. Chollet,et al.  Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  R. Ozols,et al.  Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  R. Vance,et al.  Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials. , 1994, Gynecologic oncology.

[25]  S. Rubin,et al.  Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  J. Berek,et al.  Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  E. Yordan,et al.  A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A gynecologic oncology group study , 1986, Cancer.

[28]  D. Mavroudis,et al.  Gemcitabine plus oxaliplatin (GEMOX) in pretreated patients with advanced ovarian cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG). , 2008, Anticancer research.